Welcome to our dedicated page for Moss Genomics news (Ticker: MSSGF), a resource for investors and traders seeking the latest updates and insights on Moss Genomics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moss Genomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moss Genomics's position in the market.
Moss Genomics (OTCQB: MSSGF) announced on November 11, 2025 the closing of a non-brokered private placement of 555,555 common shares at $0.18 per share for gross proceeds of $100,000.
Also effective November 11, 2025, Moss issued 5,164,213 common shares at a deemed price of $0.18 per share as consideration under asset purchase agreements (aggregate deemed consideration $966,435) to acquire approximately 224.7523 ETH at an average price of $3,833 per ETH. Following these transactions, Moss has 63,414,545 common shares outstanding. All securities are subject to applicable Canadian statutory hold periods.
An Annual and Special General Meeting is scheduled for November 13, 2025 to be held virtually; meeting materials and access instructions are posted on the company's website.
Moss Genomics (OTCQB: MSSGF) has announced progress in its Ethereum Treasury Strategy, contributing 200 ETH with a commitment for an additional 800 ETH to the STRAT presale. STRAT is an on-chain smart contract platform for ETH-based capital flows.
The company is advancing its blockchain integration strategy, following a previously announced non-binding term sheet for investment in Genomes.io, a genomics platform focused on decentralized data storage and patient privacy. The STRAT presale aims to raise 6,900 ETH from strategic investors. Moss also noted ongoing progress toward completing its February 2025 private placement financing.
Moss Genomics (CSE: MOSS, OTCQB: MSSGF) has announced two significant developments: the public launch of its genomics platform 'Perennial' and the closure of a cryptocurrency financing round.
The Perennial platform, which completed beta testing in March, enables users to upload standard blood test results and receive personalized biomarker-based health insights. The platform is now accessible at app.mossgenomics.com.
Additionally, the company has secured 130 ETH (Ethereum) at CAD $3,500 per ETH as part of its ongoing private placement, raising gross proceeds of CAD $455,000. In exchange, Moss issued 2,527,777 common shares at CAD $0.18 per share. The securities are subject to a four-month plus one-day statutory hold period.
Moss Genomics (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) has announced its listing on the OTC Markets under the ticker MSSGF. This strategic move aims to enhance share liquidity and increase accessibility for U.S.-based investors by enabling trading through U.S. broker-dealers.
The company, focused on biotechnology, is developing next-generation genomics products for personal health data management. Their current project includes testing a beta version of Perennial, a consumer platform that provides personalized health insights from blood test results based on key biomarkers.
Moss Genomics will maintain its listings on the Canadian Securities Exchange (CSE: MOSS) and Frankfurt Stock Exchange (FSE: F73).
FAQ
What is the current stock price of Moss Genomics (MSSGF)?
